Volumen: 16 # Number : 3
Publication Date : Septiembre - Diciembre Year: 2012
Authors: Bezares RF, Solessi MS, Ledesma LI
Abstract: While in the past 20 years were made great progress in
the therapy of lymphoid neoplasms with the introduction
of combination chemotherapy regimens and the addition
of biological agents, is still a challenge to find combinations
more effective and less toxic that produce complete
and prolonged remissions even in patients with relapsed
or refractory disease. Thus bendamustine, is introduced
as a new option for the management of these neoplasms.
This drug has a complex antitumor mechanism of action
that allows function even against the presence of p53 mutations.
It has demonstrated activity against CLL, MCL
and indolent NHL, both in naive patients as in refractory to conventional chemotherapies, and also has also proven
to be synergistic with rituximab.
Key words: Bendamustine, CLL, NHL, chemotherapy
Pages : 192-199
|
